TY - JOUR
T1 - The disease modifying osteoarthritis drug (DMOAD)
T2 - Is it in the horizon?
AU - Qvist, Per
AU - Bay-Jensen, Anne-Christine
AU - Christiansen, Claus
AU - Dam, Erik B
AU - Pastoureau, Philippe
AU - Karsdal, Morten A
PY - 2008/7
Y1 - 2008/7
N2 - Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, inhibitors of inducible nitric oxide synthase (iNOS), doxycycline, glucosamine, and diacereine. We discuss the challenges associated with the drug development process in general and with DMOADs in particular, and we advance the need for a new development paradigm for DMOADs. Two central elements in this paradigm are a stronger focus on the biology of the joint and the application of new and more sensitive biomarkers allowing redesign of clinical trials in osteoarthritis.
AB - Till date, the pharmaceutical industry has failed to bring effective and safe disease modifying osteoarthritic drugs (DMOADs) to the millions of patients suffering from this serious and deliberating disease. We provide a review of recent data reported on the investigation of DMOADs in clinical trials, including compounds inhibiting matrix-metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, inhibitors of inducible nitric oxide synthase (iNOS), doxycycline, glucosamine, and diacereine. We discuss the challenges associated with the drug development process in general and with DMOADs in particular, and we advance the need for a new development paradigm for DMOADs. Two central elements in this paradigm are a stronger focus on the biology of the joint and the application of new and more sensitive biomarkers allowing redesign of clinical trials in osteoarthritis.
KW - Anthraquinones
KW - Antirheumatic Agents
KW - Calcitonin
KW - Cytokines
KW - Diphosphonates
KW - Doxycycline
KW - Glucosamine
KW - Humans
KW - Matrix Metalloproteinase Inhibitors
KW - Nitric Oxide Synthase Type II
KW - Osteoarthritis
KW - Journal Article
KW - Review
U2 - 10.1016/j.phrs.2008.06.001
DO - 10.1016/j.phrs.2008.06.001
M3 - Review
C2 - 18590824
SN - 1043-6618
VL - 58
SP - 1
EP - 7
JO - Pharmacological Research
JF - Pharmacological Research
IS - 1
ER -